ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies

By The Science Advisory Board staff writers

ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further testing and possible inclusion in the company's PolyTope monoclonal antibody therapy against COVID-19.

The selected lead antibodies are the result of functional screening of over 300 antibodies analyzed from human and llama cells utilizing proprietary phage display technology. These antibodies support the company's goal of generating a multitarget therapy that retains efficacy, even as SARS-CoV-2 continues to evolve.

The company is preparing to test the lead antibodies against additional mutated strains of the virus with preclinical studies slotted to begin this summer.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: